niacin has been researched along with Idiopathic Parkinson Disease in 11 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dysbiosis is implicated by many studies in the pathogenesis of Parkinson's disease (PD)." | 2.66 | Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson's Disease. ( Karunaratne, TB; Okereke, C; Purohit, S; Seamon, M; Sharma, A; Wakade, C, 2020) |
| "Niacin is a precursor for NAD-NADH which is needed for dopamine production." | 2.50 | A novel treatment target for Parkinson's disease. ( Chong, R; Wakade, C, 2014) |
| "Niacin levels were lower in PD and were associated with increased frequency of experiencing body pain and decreased duration of deep sleep." | 1.40 | Upregulation of GPR109A in Parkinson's disease. ( Bradley, E; Chong, R; Morgan, J; Thomas, B; Wakade, C, 2014) |
| "Interestingly, pellagra and Parkinson's disease could share some basic pathophysiological mechanisms at the level of nicotinamide metabolism, resulting in mitochondrial dysfunction and alterations in dopaminergic pathways." | 1.39 | Parkinsonian features in a case of pellagra: a historical report. ( Cavanna, AE; Nani, A; Williams, AC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Abu-Elfotuh, K | 1 |
| Hamdan, AME | 1 |
| Abbas, AN | 1 |
| Alahmre, ATS | 1 |
| Elewa, MAF | 1 |
| Masoud, RAE | 1 |
| Ali, AA | 1 |
| Othman, M | 1 |
| Kamal, MM | 1 |
| Hassan, FAM | 1 |
| Khalil, MG | 1 |
| El-Sisi, AM | 1 |
| Abdel Hady, MMM | 1 |
| Abd-Elhaleim El Azazy, MK | 1 |
| Awny, MM | 1 |
| Wahid, A | 1 |
| He, D | 1 |
| Fu, S | 1 |
| Ye, B | 1 |
| Wang, H | 1 |
| He, Y | 1 |
| Li, Z | 1 |
| Li, J | 1 |
| Gao, X | 1 |
| Liu, D | 1 |
| Giri, B | 2 |
| Belanger, K | 1 |
| Seamon, M | 2 |
| Bradley, E | 2 |
| Purohit, S | 2 |
| Chong, R | 3 |
| Morgan, JC | 2 |
| Baban, B | 2 |
| Wakade, C | 5 |
| Karunaratne, TB | 1 |
| Okereke, C | 1 |
| Sharma, A | 1 |
| Malik, A | 1 |
| Khodadadi, H | 1 |
| Chong, RK | 1 |
| Thomas, B | 1 |
| Morgan, J | 1 |
| Wallach, I | 1 |
| Jaitly, N | 1 |
| Lilien, R | 1 |
| EHLERS, G | 1 |
| Moriyama, TF | 1 |
| Cavanna, AE | 1 |
| Nani, A | 1 |
| Williams, AC | 1 |
2 reviews available for niacin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson's Disease.
Topics: Animals; Butyrates; Dietary Supplements; Dysbiosis; Gastrointestinal Microbiome; Humans; Intestinal | 2020 |
A novel treatment target for Parkinson's disease.
Topics: Aged; Dopamine; Female; Humans; Male; Middle Aged; NAD; Neuroprotective Agents; Niacin; Nicotinic Ag | 2014 |
1 trial available for niacin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Niacin modulates macrophage polarization in Parkinson's disease.
Topics: Aged; Dietary Supplements; Female; Humans; Macrophages; Male; Middle Aged; Niacin; Parkinson Disease | 2018 |
8 other studies available for niacin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Evaluating the neuroprotective activities of vinpocetine, punicalagin, niacin and vitamin E against behavioural and motor disabilities of manganese-induced Parkinson's disease in Sprague Dawley rats.
Topics: Acetylcholinesterase; Animals; Anti-Inflammatory Agents; Antioxidants; Glycogen Synthase Kinase 3 be | 2022 |
Activation of HCA2 regulates microglial responses to alleviate neurodegeneration in LPS-induced in vivo and in vitro models.
Topics: Animals; Dopaminergic Neurons; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microglia; Neuro | 2023 |
Niacin Ameliorates Neuro-Inflammation in Parkinson's Disease via GPR109A.
Topics: Animals; Anti-Inflammatory Agents; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Lipopolys | 2019 |
Upregulation of GPR109A in Parkinson's disease.
Topics: Adult; Aged; Case-Control Studies; Female; Humans; Male; Middle Aged; Niacin; Parkinson Disease; Rec | 2014 |
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways.
Topics: Breast Neoplasms; Computational Biology; Databases, Factual; Diabetes Mellitus, Type 2; Drug-Related | 2010 |
[On the applicability of cosaldon in the treatment of cerebral sclerotic parkinsonism].
Topics: Drug Combinations; Niacin; Nicotinic Acids; Parkinson Disease; Parkinsonian Disorders; Theobromine; | 1959 |
Corn might prevent Parkinson's Disease.
Topics: Humans; Niacin; Parkinson Disease; Prevalence; Zea mays | 2001 |
Parkinsonian features in a case of pellagra: a historical report.
Topics: History, 20th Century; Humans; Male; Middle Aged; Parkinson Disease; Pellagra; Sciatica | 2013 |